Member Info for Muck165

I'm sure he's watching - still pops in now and again!

Lets not turn this into a negative board on what was great news today.

True, the contracts in and of themselves will not be game changing, although they may very well expand over time both in terms of sales volumes , new product additions, or both.

The real benefit here, from a retail home testing perspective, is that we can now advertise our CDMO/CRO offering as including relationships with more major retail players in the UK. That cannot hurt when trying to attract new business.

And of course retail consumer home testing is only one of many strings to ABDX bow. Perhaps bigger opportunities lie in supplying national health services with transformative tests to meet unmet need, like 52 North and Upfront, both of which we know have been fast-tracked on election by a panel of regulators and NHS leaders.

And that all ignores the massive plant pathogen, animal health, and environmental sectors we're working on.

It would just be nice if the herd could see through todays RNS and diver deeper into our potential a deeper dive. Then they might understand what most of us on here do.

? So I looked GDR and first thing I saw was their 15/3/24 announcement telling the market they were planning to raise in the next few weeks.

The Boots brand is established and trusted. No other LFT brand has anywhere near the same level of trust, possibly with the exception of some Covid tests.

And it will no doubt be cheaper than other brands.

Jamrock - if you go into the details of any MHC LFT here, you will see they’re all made in China. Other tests are made by Concepta, possibly in collaboration with ABDX going back to 2020 agreements.

https://www.boots.com/my-health-checked?paging.index=0&paging.size=21&sortBy=mostRelevant&criteria.category=MyHealthChecked

The Chinese tests, at least as far as I can see, are then white labelled by MHC before being sold in Boots.

“sold in BOOTS”

Alamo - remember the MHC LFT home LFTs are all made in China then white labelled by MHC before being sold in China. 3 parties wanting a bite of the cherry. With this new arrangement there’s only us and boot wanting a slice of the pie, and Boots retain the branding.

If I were Boots I’d expand this new ABDX arrangement over MHC any day of the week.

Let’s hope the herd look at the real potential of ABDX. Next stop, Salistick into Boots?

I do have an ignorant question….

Is it the case that we are simply providing our own Vitamin D and Iron tests to Boots for them to White Label. I’m assuming so given that Yates has confirmed we’re fulfilling material production orders during H2 24. Great if that is the case

Just goes to highlight the very wide broad and diverse mix of revenue opportunities now available to ABDX arising out of general LFT awareness, massive leaps in tech, and the extensive customer base it’s steadily built despite a few years of painful cost control. Well done to the BOD.

Yup, and there’s a very fair chance that Boots will look to further expand their self test offerings in future. Great new relationship.

Well apart from anything, it gives us a foothold with the largest U.K. pharmacy brand, which is great for us and surely must be attractive to any potential CRO/CDMO partner ultimately looking to commercialise through the retail self test market.

So that’s now Boots, Tesco, and Superdrug we have relations with. Not bad. Not bad at all.

Very nice surprise - wasn’t expecting it to be Boots!

A bit more on VenomAid and their plans to now initiate manufacturing

https://www.venomaid.com/news/venomaid-extends-its-seed-round-to-a-total-of-1-8-m-for-affordable-and-rapid-snakebite-diagnostics

Another potential one, borne purely out of mutual reactions I’ve noticed between VenomAid Diagnostics and Yates for some time. Founded in 2018 they spent a few years developing a test for Snakebite, and in 2023 attracted $1.8m seed funding to accelerate development to market and clinical testing. That is when all the reactions started and it’s not much of a leap to think some of the seed money came, and may still be coming our way.

https://www.venomaid.com/

Latest LinkedIn post Yates liked

https://www.linkedin.com/posts/venomaid_phdoftheyear-snakebite-impact-activity-7175741991522091009-jBbP?utm_source=share&utm_medium=member_desktop

Further interesting post and comment from our Liam Currivan today regarding Eco-Flo

https://www.linkedin.com/posts/liam-currivan-8bab88135_heriot-watt-university-creates-lateral-flow-activity-7175735834115985408-xiTu?utm_source=share&utm_medium=member_desktop

In case anyone missed it by the way, at about 2.43 in the pitch link I gave earlier in this thread, LVOne talk about how their test might be priced, saying “LVOne could be sold at a maximum of £620 and still be cost effective to the U.K. Healthcare system NHS.”

Now whether or not that’s anywhere close to final pricing is anyone’s guess, and so would be our % cut as manufacturer, but talking of many hundreds of pounds for a single test gives an idea of revenue potential here. Remember, the real value of LVOne is in the massive long term cost saving resulting from earlier, even 90 minute earlier, diagnosis, and that may well be worth the NHS shelling out that kind of money. And not to forget, NHS leaders were on the panel that chose Upfront as winners.

Again just for info but a company called NordicDx, which develops aquaculture tests to monitor fish health (presumably in farms) put this out today.

https://www.linkedin.com/posts/tommy-selnes-101a9653_nordicdx-revolusjonerende-teknologi-for-activity-7175375881006104576-vdUW?utm_source=share&utm_medium=member_desktop

As you will see, it’s in Norwegian and completely innocuous, but despite that both Chris Yates and our sales Director, Liam Currivan liked it. It relates to this article which describes a new digital reader for their LFT

https://nordicdx.no/en/nordicdx-no-innovativ-fiskehelseovervaking-digitalisering-hurtigtester-lfa/

I can’t think of any reason why both these ABDX guys would react to it unless we were somehow involved. Could be wrong.

Just for info but ABDX posted a job advert for a full time Supply Chain Assistant at the beginning of the month, and for a Part Time Buyer within the supply chain yesterday

https://www.google.com/search?q=jobs+at+abingdon+health&rlz=1C1BFEM_en-gbGB1004GB1004&oq=jobs+at+abingdon+health&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRifBTIHCAUQIRifBTIHCAYQIRifBTIHCAcQIRifBTIHCAgQIRifBTIHCAkQIRifBdIBCDU2ODNqMGo0qAIAsAIA&sourceid=chrome&ie=UTF-8&ibp=htl;jobs&sa=X&ved=2ahUKEwihrteZrv6EAxUFS0EAHV7fBVMQkd0GegQIEBAB#fpstate=tldetail&htivrt=jobs&htiq=jobs+at+abingdon+health&htidocid=u_H6W8dAPmMquULfAAAAAA%3D%3D

What exactly is behind this is anyone's guess, but both roles seem geared to the manufacturing arm of the business so it could relate to improved Salistick sales, the new OEM contract orders Yates has told us about, something else, or it could just be he's replacing staff that have left!

Pretty mundane stuff I know, but always good to be aware of these things.

Another quiet day...

The only thing that's interesting is that all but one of the transactions today have been sells, yet each of those sells was transacted at a higher price than the last. So the actual bid is rising even though all we are seeing is sells.

And I noticed in the auction this morning that we had two Direct Market Access offers for stock, one for 100,000 at 8.5, and the other at 7999 at 9.

So I am wondering if these two things might indicate a sizeable buy order in the background, although I freely admit that's outside of my competence so would appreciate any insights others might give.